Drug intelligence / Profile preview

NST0078

Development stage: Preclinical
Lead developer: Neuron Biopharma
Modality: Small Molecules

Overview

NST0078 is a small molecule drug candidate developed by Neuron Bio for the treatment of Mild Cognitive Impairment (MCI). Developed within the company's neuropharma division, the compound is part of a pipeline focused on neurodegenerative and central nervous system disorders. As of the available data, NST0078 has progressed through preclinical screening and efficacy stages and is moving toward regulatory-enabling studies. The specific molecular target and mechanism of action for NST0078 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on NST0078.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST0078.

Explore the full profile